News

October 30, 2025

Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor

December 6, 2024

Vincent Aurentz Joins Forward Therapeutics’ Board of Directors

September 3, 2024

Forward Therapeutics Welcomes Ulrich Thienel, M.D., Ph.D. as Chief Medical Officer

January 8, 2024

Forward Therapeutics welcomes Ajay Madan, Ph.D., as Chief Development Officer

October 31, 2023

Forward Therapeutics Announces $50 Million Series A Financing